Health TrialsbyHealthPanel

Tecar Therapy in Chronic Knee Osteoarthritis

ConditionOsteearthritis
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorKirsehir Ahi Evran Universitesi

About this trial

This study aimed to investigate the effects of Tecar therapy on pain, physical function, and physical capacity in patients with chronic knee osteoarthritis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with Kellgren-Lawrence stage 2 or 3 knee osteoarthritis

Patients with bilateral knee pain for at least 6 weeks

Male and female patients aged 40-75

Patients who accept and sign the informed consent form

Disqualifiers

Those who have received physical therapy for knee pain in the last 6 months

Those who have received intraarticular injection treatments such as hyaluronic acid, PRP, or steroids for knee pain in the last 6 months

Those who have undergone knee surgery for any reason

Those with inflammatory arthritis

Trial design

Design model

Parallel

Treatments tested in this trial

  • Tecar Therapy

    Other intervention

    Tecar Therapy and conventional physical therapy

  • ShamTecar Therapy

    Other intervention

    ShamTecar Therapy and conventional physical therapy

  • conventional physical therapy

    Other intervention

    conventional physical therapy

Treatment groups

60 Participants
are divided into 3 treatment groups
Group A: Tecar theraphyExperimental treatment 2 interventions
Group B: Sham tecar theraphyExperimental treatment 2 interventions
Group C: conventional physiotherapyExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Visual Analog Scale

VAS is a pain rating scale with numbers 0 and 10. Here 0 means 'no pain' and 10 means 'unbearable pain'. The participant will rate the pain according to the scale. Patients' night, rest and activity pain will be evaluated separately.

Time frame
baseline, 3th week, 12th week

Secondary outcomes

1

WOMAC

WOMAC consists of three main subgroups: pain, stiffness, and difficulty performing daily activities. It is a questionnaire with a total of 24 questions. Each question has five alternative answers: none, mild, moderate, severe, and very severe. Scoring is given as follows: pain (maximum 20), stiffness (8), and difficulty performing daily activities (68). High scores indicate worsening symptoms, significant limitations, and insufficient overall health. The Turkish version of the scale was developed by Tüzün et al. in 2005.

Time frame
baseline, 3th week, 12th week
2

The 6-minute walk test (6MWT)

The 6-minute walk test (6MWT) will be used to assess physical capacity. Patients will be asked to walk at their preferred pace for 6 minutes in a 30-meter corridor marked at 3-meter intervals. Rest periods or adjustments to walking speed will be allowed if necessary. The maximum distance covered in 6 minutes along the 30-meter corridor will be measured.

Time frame
baseline, 3th week, 12th week

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Kirsehir Ahi Evran Universitesi

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: